Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.
IPO Year: 2017
Exchange: NASDAQ
Website: immuron.com.au
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Immuron Ltd (0001660046) (Issuer)
3 - Immuron Ltd (0001660046) (Issuer)
3 - Immuron Ltd (0001660046) (Issuer)
3 - Immuron Ltd (0001660046) (Issuer)
3 - Immuron Ltd (0001660046) (Issuer)
3 - Immuron Ltd (0001660046) (Issuer)
3 - Immuron Ltd (0001660046) (Issuer)
3 - Immuron Ltd (0001660046) (Issuer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
Fastest customizable press release news feed in the world
MELBOURNE, Australia, July 20, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Kalkine Media Webinar on Monday, 20th July 2026 (12:30pm Australian Eastern Time). A copy of the presentation slide deck is available on the Company’s website: https://investors.immuron.com.au/announcements/7639968 This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT:Steven LydeamoreChief Executive Officersteve@immuron.com About ImmuronImmuron Limited ((ASX: IMC, NASDAQ:IMRN), is an Australian biopharmaceutical company focused on developing and commerci
Sales Highlights (unaudited):Global FY26 sales AUD$7.7 million up 6% on prior comparative period (pcp)2H FY26 sales AUD$3.5 million up 7% on pcp4Q FY26 sales AUD$2.0 million up 2% on pcp Australia FY26 sales AUD$5.8 million up 10% on pcp2H FY26 sales AUD$2.5 million up 6% on pcp4Q FY26 sales AUD$1.6 million up 1% on pcp Canada FY26 sales AUD$0.2 million down 55% on pcp2H FY26 sales AUD$0.1 million up >1000% on pcp4Q FY26 sales up 376% on pcp USA FY26 sales AUD$1.8 million up 7% on pcpFY26 sales USD$1.2 million up 13% on pcp 2H FY26 sales AUD$0.9 million down 1% on pcp2H FY26 sales USD$0.6 million up 9% on pcp
Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering StrategyImmuron is seeking a partner to support clinical development through regulatory approval and commercializationImmuron has U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) applicationIND 32095 is Immuron’s Investigational new drug (IND) application for clinical development of IMM-529 as a product to specifically prevent or treat Clostridioides difficile infection (CDI) MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to announce that it has engaged Pullan Consulting to provide business development services
MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 92nd Emerging Growth Conference on May 6 & 7, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter. Presenting today – Wednesday, May 6, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on May 6 & 7, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayMay 6, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to the re
Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp)YTD Mar 2026 sales AUD$5.7 million up 7% on prior comparative period (pcp) Australia Q3 sales AUD$0.9 million up 15% on prior comparative period (pcp)YTD Mar 2026 sales AUD$4.2 million up 14% on prior comparative period (pcp) Canada Q3 sales AUD$0.1 million up >100% on prior comparative period (pcp)Q3 sales up 82% on prior quarter; initial sales to Jean Coutu, QuebecYTD Mar 2026 sales AUD$0.1 million down 65% on prior comparative period (pcp) USA Q3 sales AUD$0.5 million up 1% on prior comparative period (pcp)YTD Mar 2026 sales AUD$1.3 million up 10% on prior comparative period (pcp)
MELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Coffee Microcaps Conference on Thursday 5th March 2026 (11:00am – 11:30am Australian Eastern Time). A copy of the presentation slide deck is available on the Company's website: https://investors.immuron.com.au/announcements/7418301 COMPANY CONTACT: Steven LydeamoreChief Executive Officersteve@immuron.com About ImmuronImmuron Limited ((ASX: IMC, NASDAQ:IMRN), is an Australian biopharmaceutical company focused on developing
Highlights (unaudited): Consistent Revenue Growth: Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash (AUD $10.0 million) to fund operating activities. Includes AUD $7.3 million (net) raised at an average price of A$0.0803 (IMRN USD$2.0923).Validated Platform: The "Hyper-Immune" platform is versatile. Beyond traveler's diarrhea (Travelan®), the company is moving into high-value clinical targets like C. diff (IMM-529)Partnerships: Immuron has taken a strategic decision to pursue partnerships to fund progress of Travelan® (IMM-124E) and IMM-529 clinical programs. IMM-124E: Eligible for end o
MIAMI, Jan. 21, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 89th Emerging Growth Conference on January 21 & 22, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - Presenting Today - January 21, 2026 8:45Virtual Lobby opens.Register for the Conference. If you alread
MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 89th Emerging Growth Conference on January 21 & 22, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayJanuary 21, 2026 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba
Live Leadership Updates
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed as a Director in 2012 and served as Non-Executive Chairman from 2012 to 2023. Immuron over the past few years has been ongoing with significant positive change. We have accelerated our commercial activities through higher level of marketing, improved channel management and strategic intent. Our scientific endeavours are bearing results with strong clinical data supporting IMC's unique hyper-immune colos
MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Steven Lydeamore as Chief Executive Officer (CEO) of the Company effective 27 June 2022. Mr. Lydeamore has 30 years international pharmaceutical experience, working in Australia, Canada and USA. Mr. Lydeamore brings valuable international experience having spent eleven years working at Canadian global pharmaceutical company Apotex Inc., and four years for Mayne Pharma (USA) Limited. This i
MELBOURNE, Australia, March 16, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Paul Brennan as an independent Non-Executive Director of the Company with effect from today. Mr Brennan has extensive experience in the health system through his clinical background and commercial exposure with various multinational companies. Mr Brennan was Chief Executive Officer (CEO) of PolyNovo Limited (ASX:PNV) for 7 years from 2015 to 2021 and took the company from $30M to a high